Author:
Stock Wendy,Undevia Samir D.,Bivins Carol,Ravandi Farhad,Odenike Olatoyosi,Faderl Stefan,Rich Elizabeth,Borthakur Gautam,Godley Lucy,Verstovsek Srdan,Artz Andrew,Wierda William,Larson Richard A.,Zhang Yanming,Cortes Jorge,Ratain Mark J.,Giles Francis J.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,Oncology
Reference10 articles.
1. Aribi A, Ravandi F, Giles F (2006) Novel agents in acute myeloid leukemia. Cancer J 12:77–91
2. LoRusso PM, Parchment R, Demchik L et al (1998) Preclinical antitumor activity of XK469 (NSC 656889). Invest New Drugs 16:287–296
3. Gao H, Huang KC, Yamasaki EF et al (1999) XK469, a selective topoisomerase IIbeta poison. Proc Natl Acad Sci U S A 96:12168–12173
4. Kessel D, Horwitz JP (2001) Pro-apoptotic interactions between XK469 and the peripheral benzodiazepine receptor. Cancer Lett 168:141–144
5. Lin H, Subramanian B, Nakeff A et al (2002) XK469, a novel antitumor agent, inhibits signaling by the MEK/MAPK signaling pathway. Cancer Chemother Pharmacol 49:281–286
Cited by
9 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献